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Abstract
Urinary incontinence, defined as the complaint of any involuntary loss of urine, is a pathological condition, which affects
30% females and 15% males over 60, often following a progressive decrease of rhabdosphincter cells due to increasing age
or secondary to damage to the pelvic floor musculature, connective tissue and/or nerves. Recently, stem cell therapy has
been proposed as a source for cell replacement and for trophic support to the sphincter. To develop new therapeutic
strategies for urinary incontinence, we studied the interaction between mesenchymal stem cells (MSCs) and muscle cells in
vitro; thereafter, aiming at a clinical usage, we analyzed the supporting role of MSCs for muscle cells in vitro and in in vivo
xenotransplantation. MSCs can express markers of the myogenic cell lineages and give rise, under specific cell culture
conditions, to myotube-like structures. Nevertheless, we failed to obtain mixed myotubes both in vitro and in vivo. For in
vivo transplantation, we tested a new protocol to collect human MSCs from whole bone marrow, to get larger numbers of
cells. MSCs, when transplanted into the pelvic muscles close to the external urethral sphincter, survived for a long time in
absence of immunosuppression, and migrated into the muscle among fibers, and towards neuromuscular endplates.
Moreover, they showed low levels of cycling cells, and did not infiltrate blood vessels. We never observed formation of cell
masses suggestive of tumorigenesis. Those which remained close to the injection site showed an immature phenotype,
whereas those in the muscle had more elongated morphologies. Therefore, MSCs are safe and can be easily transplanted
without risk of side effects in the pelvic muscles. Further studies are needed to elucidate their integration into muscle fibers,
and to promote their muscular transdifferentiation either before or after transplantation.
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Introduction
Urinary incontinence (UI), defined as the complaint of any
involuntary loss of urine, represents an increasingly frequent
pathological condition, which occurs in 30% females and 15%
males aged over 60. Stress urinary incontinence (SUI) is
‘‘complaint of loss of urine on effort or physical exertion or on
sneezing or coughing’’ while urodynamic stress incontinence (USI)
is ‘‘involuntary leakage during filling cystometry, associated with
increased intra-abdominal pressure, in the absence of a detrusor
contraction’’ [1]. An important cause of SUI is a progressive
decrease of rhabdosphincter cells due to increasing age, which is
caused by physiological apoptosis [2]. The significant progressive
decrease in the number of striated muscle cells in the rabdo-
sphincter with ageing represents a pathogenetic hypothesis for the
high incidence of incontinence. Several different etiologies have
been identified, such as ageing, obesity, multiple labors and
prostatic surgery. The pathogenetic mechanism consists in
a damage to the pelvic floor musculature, connective tissue and/
or nerves. The outcome is urethral hypermobility and sphincter
deficiency, isolated or in combination. Pharmacology failed to
treat the disease: for instance, alpha agonists had no significant
effect on the incontinence [3]. Several bulking agents have been
proposed [3,4]. Even though some of them have improved
continence in selected patients, many unwanted side effects have
been described [4,5]. Moreover, treatment often fails in the long-
term [6]. Non-invasive treatment is likely to be offered in mild
cases and may entail pelvic floor muscle re-education.
Surgical approaches such as sling procedures and bladder neck
suspensions are more efficacious [7]. These procedures are
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effective but can bear side effects such as bladder and urethral
lesions or urinary retention. Other options, such as adjustable
continence therapy (pro-ACT, consisting of two balloons placed at
the bladder neck) may be considered in specific situations [8]. The
optimal surgery has not yet been clearly established and current
therapies for SUI do not treat pathophysiologic causes [9]. Future
treatment paradigms may prioritize improving urethral sphincter
function rather than urethral support [10].
Recently, stem cell therapy emerged as a revolutionary and
useful tool for many diseases [11]. Therefore, it has been proposed
as a source for cell replacement in SUI and for trophic support to
the sphincter [4,12]. Some studies pointed out the possibility of
treating SUI with stem cells from muscle biopsies [13]. Mesen-
chymal Stem Cells (MSCs) represent an alternative source for cell
therapy. MSCs can be isolated from different organs or tissue
compartments including bone marrow (BM), umbilical cord blood,
umbilical cord stroma (Wharton’s jelly), placenta, adipose tissue,
amniotic fluid, dental pulp and many others [14].
In an autologous context of regenerative medicine bone
marrow-derived mesenchymal stem cells (BM-MSCs) are ideal
for transplantation: they are easily collected from the same patient
and are renewable, multipotent cells. They can differentiate into
various mesodermic cytotypes, including osteoblasts, chondro-
cytes, adipocytes [15,16], tenocytes, myocytes and stromal cells,
and act as minipumps, delivering trophic factors and immuno-
modulatory molecules [17]. Moreover, they present reduced risk
of eliciting immunoreaction, due to their immunomodulatory
potential, and minor side effects in terms of tumorigenesis than
embryonic stem cells. The particular characteristics and high
plasticity of BM-MSCs make them ideal candidates in cell therapy
strategies to treat a number of degenerative [18,19] and post-
traumatic diseases caused by damage or cell loss [20,21].
In an attempt to develop new therapeutic strategies for urinary
incontinence we studied the interaction between MSCs and
muscle cells in vitro; thereafter, aiming at a clinical usage in SUI, we
analysed the supporting role of MSCs for muscle cells in vitro and
in in vivo xenotransplantation. In keeping with the aim of treating
SUI with MSCs, we tested a system to collect BM-MSCs from
whole bone marrow, in order to get larger numbers of cells. We
aimed a) to study the potential for myogenic differentiation in vitro
of BM-MSCs alone and in co-culture with muscle cells, and b) to
study their survival, proliferation and differentiation in vivo
following transplantation into the perineal muscles. First of all,
we isolated, cultured and characterized mouse BM-MSCs to be
cocultured with C2C12 mouse skeletal myoblasts [22]. Then, we
characterized the myogenic potential of human BM-MSCs in vitro,
to be transplanted into the pelvic muscles of male rats.
Materials and Methods
a) Co-culture of Mouse BM-MSCs and Myoblasts
Isolation and culture of mouse BM-MSCs (BM-
mMSCs). BM-mMSCs were obtained from BCF1 mice, ex-
pressing enhanced green fluorescent protein (EGFP) under the
beta-actin promoter, kindly provided by Dr. M. Okabe (Osaka
University, Suita, Japan [23]). Seven-to-nine week-old EGFP mice
were killed by cervical dislocation; their tibias and femurs were
cleared of muscle and connective tissue. Bone marrow cells were
aspirated using a 22-gauge needle, and washed twice for 5 minutes
each by centrifugation at 150 g in Eagle’s alpha minimum
essential medium (a-MEM; Sigma, St. Louis, MO, USA),
containing 2 mM L-glutamine (Invitrogen-Gibco¸ Carlsbad, CA,
USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Invitro-
gen-Gibco). Cells were seeded in polystyrene 19.5 cm2 dishes (BD
Biosciences) pre-treated with a coating of foetal bovine serum
(FBS; Sigma); cells were grown in a-MEM supplemented with
10% FBS, in a humidified atmosphere of 95% air with 5% CO2 at
37uC. Medium was replaced on day 4 to remove free floating cells,
and then replenished every 2–3 days. At 10 days in vitro, adherent
cells were retrieved by trypsinization (Trypsin, Invitrogen-Gibco)
and immunodepleted of CD11b-positive granulocytic cells by
magnetic cell sorting: cells were incubated with MicroBeads
conjugated to monoclonal rat anti-mouse/human CD11b anti-
body (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and
loaded onto a MACS column (Miltenyi Biotec). CD11b-negative
cells were harvested, washed and re-plated onto dishes as
described above. When the cells were near confluence, they were
washed with a-MEM medium and incubated with trypsin for
5 min at 37uC. Trypsin was neutralized by adding fresh complete
medium. The cellular suspension was diluted 1:2 at each passage.
C2C12 cell culture and differentiation. C2C12 mouse
skeletal myoblasts from ATCC (ATCC-LGC Standards S.r.l.,
Sesto San Giovanni (MI), Italy) were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) high glucose (Sigma) with
10% FBS (Sigma), containing 2 mM L-glutamine, 100 U/ml
penicillin and 100 mg/ml streptomycin (all purchased from
Invitrogen-Gibco). Cells were maintained in a humidified atmo-
sphere of 95% air with 5% CO2 at 37uC. When at confluence,
cells were detached with trypsin, as previously described, and split
1:5. In order to allow C2C12 myoblasts to differentiate into
myotubes, the serum concentration was reduced to 3% and
maintained in culture with media changes every 2 days.
Co-culture of C2C12 and BM-mMSCs. C2C12 cells and
BM-mMSCs were co-cultured at the ratio of 1:4, in DMEM-high
glucose (Invitrogen) containing 10% FBS (Sigma), containing
2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml strepto-
mycin (Invitrogen). The ratio of 1:4 of C2C12/BM-mMSCs was
chosen after a literature survey, considering the cellular growth
respectively very fast for C2C12, and markedly slow for murine
MSCs. Several different ratios have been proposed for the
coculture of MSCs and myoblasts [24–27]. After 2 days of co-
culture, growth medium was substituted with differentiation
medium, consisting of DMEM high glucose (Sigma) with 3%
FBS (Sigma). Fresh differentiation medium was added every 2–3
days until 4 weeks.
Immunofluorescence of cell cultures. Cells were fixed in
4% paraformaldehyde (PFA) in PBS for 15 min at room
temperature. Cells were then permeabilized with PBS containing
0.3% Triton X-100 for 10 min. After blocking unspecific binding
sites with 1% BSA in PBST for 30 min at room temperature, cells
were incubated in the primary antibody (monoclonal anti-human
desmin, made in mouse, 1:50; Dako, Denmark) made up in the
same solution at 4uC overnight. After washing in PBS, samples
were incubated in 1:200 cyanine 3-conjugated secondary anti-
bodies anti-mouse (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) in PBS, for 1 hour at room temperature. For
counter staining, cells were incubated 2 min with 0.001 g/ml
Bisbenzimide in PB 0.1 M and rinsed with PBS. Finally coverslips
were mounted with a drop of PB 0.1 M. The samples were
examined with a Leica TCS SP5 confocal laser scanning
microscope (Leica Microsystems, Milan, Italy).
b) Characterization of Myogenic Potential of BM Human
MSCs (BM-hMSCs)
BM-hMSC isolation and expansion. Whole Bone Marrow
(wBM) hMSCs were isolated from BM obtained by aspiration
from the posterior iliac crest of five healthy donors after written
informed consent in accordance with the approval of the ethics
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committee of the hospitals OIRM-S.Anna-Mauritian order. BM-
hMSC frequency in BM was about 1/104 cells [28]. Briefly,
wBM was seeded at a density of 100,000/cm2 in Mesenchymal
Stem Cell Growth Medium (MSCGM) medium (Lonza, Basel,
Switzerland) in 75 or 150 cm2 T-flasks and maintained at 37uC
with an atmosphere of 5% CO2. After 5 days, the non-adherent
cells were removed and re-fed every 3–4 days; at confluence,
they were detached, and re-plated at 1,000 cells/cm2 density for
one to four passages [29]. The cells were analysed for
immunophenotype, differentiation potential and were used for
all in vivo and in vitro experiments. The cellular expansion
growth rate of MSCs was evaluated by cell count in a Burker
Chamber at each passage and expressed in terms of population
doubling (PD) using the formula log N/log 2, where N is the
cell number of the confluent monolayer divided by the initial
number of cells seeded [28].
Cytofluorimetric analysis. The characterization of wBM-
hMSCs was performed by flow cytometry analysis at each passage.
Briefly, 200,000–250,000 cells were stained for 20 minutes with
anti-CD45 Fluorescein Isothiocyanate (FITC), CD14 Phycoery-
thrin (PE), CD34 Allophycocyanin (APC), CD90 FITC, CD73 PE,
CD29 APC, CD44 FITC (Becton Dickinson, San Jose, CA, USA),
CD105 FITC (Immunostep, Salamanca, Spain). Viability was
evaluated by adding 7- aminoactinomycin D (AAD) (Becton
Dickinson). The labeled cells were thoroughly washed with PBS
and analyzed on Facs Canto II (Becton Dickinson) with the Facs
Diva software program. The positive cell percentage was
calculated using cells stained with Ig FITC/PE/APC as a Negative
Control.
Differentiation potential assay (data not shown). For
differentiation experiments, wBM-hMSCs were cultured in
osteogenic, adipogenic and chondrogenic medium (Lonza) accord-
ing to the manufacturer’s instructions. Briefly, 20,000 and 50,000
cells were plated in a T-25 flask for osteogenesis and adipogenic
culture conditions respectively, allowing the cells to adhere to the
culture dish for 24 hours in MSC medium (Lonza). To induce
osteogenesis and adipogenesis, the medium was replaced with
specific complete induction medium (Lonza). After 21 days,
osteogenic differentiation was demonstrated by the accumulation
of calcium (crystalline hydroxapatite detection by Von Kossa
staining) in separated cells plated in chamber slides in the same
culture conditions.
For the adipogenic differentiation, adipogenic induction and
maintenance medium were alternatively used every 3–4 days and
the presence of intracellular lipid vesicles visible after 2–3 weeks’
culture was assessed by Oil Red O staining.
For chondrogenic differentiation, an aliquot of 250,000 cells was
washed twice in incomplete chondrogenic medium (Lonza) in
15 ml polypropylene culture tubes. Finally, the cells were
resuspended in complete chondrogenic medium, centrifuged
and, without aspirating the surnatant, the tubes were incubated
at 37uC, in a humidified atmosphere of 5% CO2. Chondrogenic
differentiation was obtained growing cells as free-floating aggre-
gates in suspension culture with Transforming Growth Factor
(TGF)-beta3. The pellet was paraffin-embedded and stained with
Alcian Blue to identify the presence of hyaluronic acid and
sialomucin.
Myogenic differentiation. To test the differentiation poten-
tial of wBM-hMSCs towards myogenic lineage we induced
myogenic differentiation of BM-hMSCs at the first–fourth
passages as follows. We tried to translate, to wBM-hMSCs, the
promising differentiating conditions used by Gowronska-Kozak B
and coll., in a mouse model [30]. To this purpose we used all
materials and reagents suitable for human cell growth. Briefly,
5,000 wBM-hMSCs/well were seeded on collagen, laminin,
gelatin and fibronectin coated matrix (Becton Dickinson Labware,
NJ, USA) in Dulbecco’s Modified Eagle Medium (DMEM–F12,
Invitrogen, San Giuliano Milanese, Milan, Italy) supplemented
with 15% of FBS. Forty-eight hours after plating, the medium was
removed and the cells were washed with Hanks’ Balanced Salt
Solution (HBSS; Sigma, Saint Louis, MI, USA). The cells were
then cultured in DMEM-F12 with 0.1% of Insulin Transferrin
Selenium (ITS; Invitrogen), 5% of FBS and 0.2 mg/ml Epidermal
Growth Factor (EGF; Sigma) for 7 days.
Immunocytochemistry. Since we obtained the best differ-
entiation towards myogenic lineage by culturing wBM-hMSCs on
laminin coated matrix, using DMEM F12 with ITS, EGF and 5%
FBS, we evaluated myogenic differentiation of basal wBM hMSCs
and laminin cells. We performed immunocytochemistry analysis
for myogenic markers at 7 days in vitro, when we observed the
presence of binucleated cells. Human Skeletal Muscle Myoblasts
(HSMM, Lonza) were used as positive control. HSMM were
cultured in Skeletal Muscle Myoblast Cell Medium-2 (Lonza)
according to data sheet.
The cells were fixed and permeabilized with acetone-methanol
(1:1) at 220uC for 20 minutes. Non-specific binding sites were
blocked with 0.1% human serum albumin (HSA) in PBS 1X. The
cells were incubated with the primary antibody: anti-Myogenin
(1:500, Chemicon, Temecula, USA), anti-Desmin (1:20, Chemi-
con); anti-Sarcomeric Actin (SA) (1:100, Dako Cytomation,
Glostrup, Denmark); anti-Alpha Smooth Muscle Actin (a-SMA)
(1:100, Dako); anti-Myosin (1:10, Sigma, Taufkirchen Germany).
Binding was revealed by CY3-coupled anti-rabbit (1:1000,
Immunological Sciences, Rome, Italy) and Alexa fluor 488-
coupled anti-mouse (1:200, Molecular Probes, Oregon, USA)
secondary antibodies. All incubations were performed for 1 hour
at room temperature or at 4uC, overnight. Before each step, the
cells were washed in 1% HSA PBS.
PCR for L-type Ca2+ ion channel. We performed Ca2+ ion
channel analysis in wBM-hMSCs compared to cells differentiated
on laminin-coated matrix. Reverse Transcriptase-Polymerase
Chain Reaction (RT-PCR) for calcium ion channel (a1C, a1D and
a1S) expression was performed in 25 ml reaction mixture as
follows: 100 ng of cDNA, 1X reaction buffer, 1.25 mM MgCl2,
0.2 mM of each deoxynucleotide triphosphate, 0.6 mM of each
forward and reverse primer, and 1.25 U of Taq Gold Polymerase.
The forward and reverse primers were previously reported [31].
The amplification conditions were: 94uC for 10 min, 40 cycles of
94uC for 45 s, annealing for 1 min, 72uC for 1 min and a final
extension at 72uC for 7 min. The annealing temperatures were
56uC for a1C subunit, 58uC for a1D and 60uC for a1S. The PCR
products were electrophoresed through a 1.5% agarose gel and
amplicon bands were visualized by ethidium bromide staining
using Gel Doc 2000 (Biorad, UK).
c) Transplantation of BM-hMSCs in Rats
Ethical statement. Male adult Sprague-Dawley (Harlan,
Italy) weighing 250–350 g were used in this study. All animal
experimental procedures were approved and carried out in strict
accordance to European Community Council Directive 86/609/
EEC (November 24, 1986), Italian Ministry of Health and
University of Turin institutional guidelines on animal welfare
(law 116/92 on Care and Protection of living animals undergoing
experimental or other scientific procedures; authorization number
17/2010-B, June 30, 2010) and ad hoc Ethical Committee of the
University of Turin.
Prelabelling of BM-hMSCs. Cells expanded for the first 3–8
passages were labelled by adding to the medium 10 mg/ml
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bisbenzimide (Sigma, St. Louis, MO, USA), which binds DNA,
24 h before transplantation. Then the cells were detached with
Trypsin/EDTA, washed and re-suspended in saline solution to
obtain a final concentration of 50,000 cells/ml to be used for
transplantation.
Study design and surgical procedures. All experimental
procedures on live rats were done according to the European
Communities Council Directive (86/609/EEC) and following the
guidelines for care and use of laboratory animals as published by
Italian Ministry of Health (DDL 116/92). Animals had free access
to food and water. All efforts were made in order to minimize the
number of animals used and their suffering. Rectal temperature
was maintained at 36.5–37.5uC throughout the procedure with
a heating pad. Sprague-Dawley rats were used to assess survival,
migration and differentiation of BM-hMSC after transplantation
into striated muscles. Rats were randomly divided into 3 groups,
which were evaluated 24 hours (n = 3, group A), 1 month (n= 5,
group B) or 4 months (n = 4, group C) after stem cell trans-
plantation. Since it was impossible to limit the spread of stem cells
from the external urinary sphincter (EUS) in rats, due to its
extreme thinness, we decided to inject stem cells into the whole
group of perineal muscles, including the ischiocavernosus and the
bulbocavernosus muscles. Briefly, rats were anaesthetised with 2%
isoflurane vaporised in a 70/30 mixture of N2O/O2 and delivered
using a face mask. Under the operating microscope (Carl Zeiss
Inc., Jena, Germany) the scrotum was incised on the midline and
the testicles carefully displaced laterally. After dissecting surround-
ing tissue and fascia, the bulbar urethra was identified and the
perineal muscles were visualized. Using a 10-ml Hamilton syringe
(27.5 G), two injections (2 ml of a suspension of 50,000 cells/ml
each) per rat were performed under microscopic guidance into
perineal muscles close to the urethra. The optimal concentration
of MSCs in order to avoid cell damage during injection and to
allow the flow of the solution through the needle had been
determined in previous studies [19]. After stem cell administration,
surgical wounds were sutured and all rats were returned to the
cages. The time required for the procedure was approximately 15
minutes.
Tissue preparation. Animals were killed with an overdose of
anaesthetic at different time points after transplantation (24 hours
to 4 months) and perfused through the ascending aorta with saline
followed by the fixative (PFA 4% in 0.1 M phosphate buffer,
pH 7.4). Bulbar urethra with the surrounding perineal muscles
was collected from each rat, post-fixed in the same fixative for one
day and cryoprotected in 30% sucrose in PBS overnight. Samples
were then sectioned on the cryostat in 18 mm-thick serial sections,
mounted on chrome alum-coated slides, stained with hematoxylin
eosine to recognize transplantation site along with anatomic
reference points such as urethral wall, external urinary sphincter,
observed and photographed at the light microscope.
Immunofluorescence and histochemistry. Sections were
rinsed in PBS, then permeabilized with PBS containing 0.3%
Triton X-100, and successively washed three times in PBS. Non
specific binding sites were blocked by incubating sections 45
minutes at room temperature in 10% normal donkey serum
(Sigma-Aldrich) in 0.3% PBS-Triton X-100. Slices were immu-
noreacted overnight at +4uC in monoclonal mouse anti-human
desmin (1:50, Dako, Denmark) or rabbit polyclonal anti-Ki67
(1:400, Novocastra, UK). Desmin immunoreactivity was consid-
ered as an early marker of muscle differentiation [32]. After
washing in PBS, sections were incubated three hours at room
temperature with cyanine-2-conjugated or cyanine-3-conjugated
anti-rabbit secondary antibodies. Alfa-bungarotoxin (a-BTX)
histochemistry was performed to detect acetylcholine receptors
(Ach-Rs) in skeletal muscles sections as follows: sections were
rinsed in PBS then incubated 3 hours in a PBS solution containing
Alexa Fluor 555-conjugated a-bungarotoxin (1:1000, Molecular
Probes, Invitrogen, USA), then washed in PBS and mounted on
2% gelatin-coated slides. All processed sections were then observed
with a Leica TCS SP5 laser scanning confocal microscope (Leica
S.p.A., Milan, Italy).
Semi-quantitative analysis. In order to evaluate stem cell
survival and density within the site of transplantation, sections
were visualized at 10–206magnifications under a Nikon Eclipse
800 epifluorescence microscope (Nikon S.p.A., Sesto Fiorentino,
FI, Italy) and images were acquired and digitalized using a Nikon
Coolpix E995 digital camera. Images were then processed with
NIH ImageJ (software version 1.5.0, freely available online at
http://rsbweb.nih.gov/ij). The site of transplantation was manu-
ally outlined at the computer-interfaced microscope at the 106
lens, thus obtaining a measure of area and perimeter. The
motorized stage (Ma¨rzha¨user, Wetzlar, D) of the microscope
allowed a 0.1 mm accuracy on the xy coordinates. At 24 hours all
the stem cells were concentrated in the area of injection.
Afterwards, we used the area of the injection site as an indirect
estimate of cell scattering along the muscular tissue for any
considered time point, expressed as the largest value measured
through the sections for each sample for comparisons. Results are
presented as percentage 6 SEM (labelled cells/total number of
grafted cells).
Results
Co-culture Experiments
In order to evaluate the interplay between BM-MSCs and
muscle cells in vitro, we co-cultured mouse BM-mMSCs and
C2C12 cells. After one week in differentiation medium, myotubes
derived from the fusion of C2C12 myoblasts could be observed,
showing the typical elongated multinucleated structure (Fig. 1A),
occasionally presenting contractions. In addition, all C2C12 cells
resulted desmin-positive (Fig. 1A), the intermediate filament
particularly localized to the Z-band in sarcomeres. EGFP-positive
BM-mMSCs alone displayed a fibroblast-like morphology
(Fig. 1B): on the contrary, in co-culture with C2C12 cells, BM-
mMSCs frequently appeared elongated, with long cytoplasmic
processes (Fig. 1C–F). BM-mMSCs generally lined up following
the fibers orientation and adhering to the myotube membranes
(Fig. 1G–J). Nevertheless, fusion between BM-mMSCs and
C2C12 could not be observed in vitro; in addition, BM-mMSCs
were desmin-negative, suggesting their tendency to remain
undifferentiated. Taken together, these observations indicate that
BM-mMSCs rather support muscle cells, than being involved into
myotube formation.
Characterization of wBM-hMSCs
With the view of treating SUI with MSCs, we tested a system to
collect BM-MSCs from whole bone marrow, to get larger numbers
of cells. wBM-hMSCs were characterized following guidelines of
The International Society for Cellular Therapy [33]: as revealed
by cytofluorimetric analysis, wBM-hMSCs did not express CD45,
CD14, CD34 haematopoietic markers, whilst expressed high levels
of CD90, CD105, CD73, CD29, CD44 (Fig. 2A) and had a large
expansion of cells expressed in terms of cumulative population
doubling (PD) during passages of culture (Fig. 2B). Moreover,
wBM-hMSCs differentiated into osteoblasts, chondroblasts and
adipocytes under specific differentiation media (data not shown).
In order to use wBM-hMSCs as Cell Therapy Products (CTP) for
SUI treatment we evaluated the expression of myogenic markers
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such as a-SMA, SA, Myosin, Myogenin, and Desmin. Similarly to
human myoblast culture (HSSM), that can give rise to myotubes
(Fig. 3A), wBM-hMSCs displayed positivity for the above
mentioned myogenic markers (Fig. 3B).
Differentiation of wBM-hMSC Toward Myogenic Lineage
In order induce wBM-hMSCs to myotubes, we differentiated
these cells using coating matrix as Gowronska-Kozak et coll
reported in a mouse model [30]. To this purpose we used all
materials and reagents suitable for human cell growth. Coated
cells were monitored daily by phase contrast microscopy to
evaluate myotube formation. During the first 48 hours, when the
cells were maintained in DMEM F12 with 15% FBS, they showed
a typical fibroblast-like phenotype. After medium replacement, we
observed the presence of some binucleated cells at 7 days only after
differentiation on laminin-coated matrix (Fig. 4A). Even though
these differentiated cells continued to express the myogenic marker
(Fig. 4B), we never observed myotube formation. Only a few
binucleated structures (Fig. 4B) were positive for myogenic
markers such as desmin, SA and myogenin.
L-type Calcium Channel a-subunits Expression
On the basis of our immunohistochemical data, we investigated
the expression pattern for L-Type calcium channel a-subunits
(a1C, a1D and a1S), involved in myogenesis, in wBM-hMSCs and
in cells differentiated on laminin-coated matrix. According with
immunohistochemical results, above described, we found mRNA
expression for all L-Type calcium channel a-subunits (a1C, a1D
and a1S) in wBM-HMSC and in cells differentiated on laminin-
coated matrix. In particular, high mRNA levels of L-Type calcium
channel a1C, a1D and a1S subunits were detected at first, second
and fourth culture passages in wBM-hMSCs (Fig. 3C), and also
following culture on laminin cells in DMEM–F12 with 15% FBS,
and in laminin cells induced to myogenic differentiation with ITS
and EGF for 7 days (Fig. 4C). HSMM cells, human myoblasts that
give rise to myotubes in culture, were used as positive control for
the process of myogenesis involving L-Type calcium channel a-
subunits (a1C, a1D and a1S) (data not shown).
Survival and Migration of BM-hMSCs Transplanted into
the Rat Pelvic Muscles
We analyzed the outcome of stem cells transplantation at
different time points in order to assess not only their survival
within striated muscle, as evaluated at 24 hours, but also the
morphological changes occurring over mid-term (1 month) or
long-term (4 months). Bisbenzimide-stained BM-hMSCs could be
observed at 24 hours within the bulbocavernosus muscle, at the
boundary between muscle and urethral wall (Fig. 5A), extending
across an area of approximately 1.860.3 mm2, with a typical
round shape suggestive of an undifferentiated population of cells.
One month after engraftment, BM-hMSCs were traced at
injection site (across an area of 1.260.3 mm2) and, less numerous,
Figure 1. Mouse BM-mMSCs. (A) Desmin-positive multinucleated myotubes (nuclei labelled in blue with bisbenzimide) derived from the fusion of
C2C12 myoblasts. (B) EGFP-MSCs, plated alone, display a fibroblast-like shape. (C–F) In co-culture with C2C12 cells (desmin-positive, labelled in red),
MSCs (green) show long cytoplasmatic processes (arrow). (G–J) EGFP-MSCs adhere to desmin-positive myotubes (arrowhead). Scale bar = 50 mm.
doi:10.1371/journal.pone.0045538.g001
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at the external urinary sphincter, interspersed among muscular
fibers, revealing a predominantly elongated shape (Fig. 5B), as also
shown by adjusting the condenser lens to visualize the outline of
the cells. At 4 months, BM-hMSCs spread over an area of
2.560.4 mm2, indicating an important migration toward muscle
fibers (p,0.05). Injection site was still visible, although cellular
density appeared lower than at shorter survival times; at this level,
cells maintained a predominantly round shape, in contrast with
the elongated appearance of cells at the periphery (Fig. 5C).
Proliferation and Differentiation of BM-hMSCs
Transplanted into the Rat Pelvic Muscles
Muscle fibers were desmin-positive at any considered time
point. Bulbocavernosus and ischiocavernosus muscles appeared as
Figure 2. Cytofluorimetric and morfological analysis of a representative wBM-hMSCs. (A) Immunophenotypic analysis of wBM hMSCs
showing the negativity of haematopoietic markers CD45, CD14, CD34, and the positivity of CD90, CD29, CD73, CD105, CD44. (B) Analyses of growth
rate of wBM hMSCs in terms of cumulative PD. The graphic refers to the median cumulative values (1st passage: median 2.3 - range 1.4–2.6; 2nd:
median 4.5 - range 2.9–5.9; 3rd: median 6.4 - range 4.9–8.5).
doi:10.1371/journal.pone.0045538.g002
Stem Cell Therapy for Urinary Incontinence
PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e45538
striated structures in which transplanted cells occupied a peripheral
position, thus suggesting that BM-hMSCs can survive for long
periods within muscular tissue, although no colocalization of
markers was found, therefore we could not hypothesize any fusion
between BM-hMSCs and striated muscle (Fig. 6A). a-BTX
staining was diffuse one month after transplantation, whereas 4
months later we found that several BM-hMSCs were located close
to Ach-Rs (Fig. 6B). Finally, we carefully assessed proliferation of
BM-hMSCs with anti-Ki67 immunohistochemistry. One month
after transplantation 13%62.1 of cells were Ki67-positive vs 9.8%
63.5 (statistically not significant) counted 4 months later, thus
indicating that in both cases low proliferation occurred and
a tendency toward progressive loss of proliferative phenotype at 4
months could be assumed (Fig. 6C–D).
Discussion
Rapid progress in biotechnology and medicine led to the
development of new treatments and innovative medicinal products
containing viable cells. CTPs are medicinal products for treating
or preventing disease in human beings and their manufacturing
process have to comply with the principles and guidelines of GMP
for medicinal products for human use. Some studies suggested to
treat SUI with stem cells from muscle biopsies [13]. MSCs may
represent an alternative cell type for transplantation [4], since they
may be easily collected in the same patient and, as shown in the
present paper, expanded with minimal ex-vivo manipulation.
Moreover, they can modulate the environment and support
muscle fibers with trophic and immunomodulatory molecules.
The novelty of our approach consists in the usage of wBMMSC
as CTP, in order to obtain a large amount of MSCs starting from
few mL of BM aspirate, with a minimal ex-vivo manipulation [29].
Here, we performed in vitro studies to assess the capability of MSCs
i) to differentiate into muscle cells or ii) to integrate with myogenic
cell lines. To the first aim, we cultured wBM-hMSCs, the ones to
be later used in vivo. To the second aim, we studied the mouse-to-
mouse interaction, by culturing undifferentiated mouse MSCs
with a myogenic cell line. In order to assess the feasibility of
translation of MSC transplantation into clinics, and to exclude
negative side effects, we performed an in vivo study in which we
transplanted wBM-hMSCs in the rat perineal muscle. To our
knowledge, this is the first study to transplant wBM-hMSCs,
expanded without gradient separation, and to show the long term
survival in situ of grafted cells in absence of immunosuppression
and without side effects such as teratoma formation or un-
controlled cell proliferation.
Figure 3. Immunofluorescence and Molecular analysis of Calcium ion channel subunits in wBM-hMSC. (A) Positive control normal Human
Skeletal Muscle Myoblast (HSMM). Scale bar = 10 mm (alpha SMA) and 25 mm (SA, Myosin, Myogenin and Desmin). (B) Undifferentiated wBM hMSC
analyzed at 28 days. Scale bar = 10 mm (a-SMA), 25 mm (SA, Myosin, and Desmin), 50 (Myogenin). (C) Original gels demonstrating amplification of
calcium ion channel subunit transcripts in wBM hMSCs: -RT: control of reverse transcription without RT enzyme; C2: negative control (water); C+:
positive control (HSMM); line 1: wBM hMSCs from first passage; line 2: wBM hMSCs from second passage; line 3: wBM hMSCs from fourth passage; b-
actin, housekeeping gene.
doi:10.1371/journal.pone.0045538.g003
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Myogenic differentiation of MSCs has been previously reported,
although some controversy remains [34]. Our results show that
wBM-hMSC, even though they have a fibroblastoid, and not
tubular, shape, express basally myogenic markers. Undifferentiat-
ed wBM-hMSCs express many myogenic markers, such as a-
SMA, SA, myosin, myogenin, desmin, maintaining immunophe-
notypical characteristics and functions as multipotent cells. Our
data are in agreement with those which show the expression of a-
SMA, MYOD1 and MyHC in native MSC and AZA-exposed
MSC, isolated by gradient density [35], and of desmin, myogenin,
a-SMA by immunohistochemistry and RT-PCR in BM-hMSCs
[36]. The expression of desmin by hMSCs seems to contradict
with the failure of desmin expression by mMSC: to explain this
finding, we hypothesize that human and murine MSCs can display
a partially different cell-surface antigenic profile. For example,
Stro-1, which is expressed by BM-hMSCs, has no known mouse
counterpart [37]. Therefore, some myogenic markers might be
more evident in human than in murine MSCs.
In addition to the in vitro expression of myogenic markers, we
considered the expression of L-type channel a-subunits in BM-
hMSCs to monitor their differentiation into muscle cells. In-
tracellular free Ca2+ is a fundamental biological signal regulating
a number of cell functions. For instance, it plays an important role
in controlling cell growth, transformation, secretion, smooth
muscle contraction, sensory perception and neuronal signaling
[38,39]. Spontaneous intracellular free Ca2+ oscillations are
present in MSCs. Nevertheless, their physiological functions in
MSCs are still elusive [40], and Ca2+ channel expression in BM-
Figure 4. Myogenic differentiation on laminin matrix and L-type Calcium ion channel subunits analysis. (A) Phase contrast images of
laminin cells: presence of some binucleated cells. Scale bar = 25 mm. (B) Immunofluorescence analysis confirmed the presence of a few binucleated
structures positive for desmin, SA, myogenin in BM-hMSC cultured on laminin cells. Scale bar = 25 mm. (C) Original gels demonstrating amplification
of calcium ion channel subunit transcripts in laminin cells: –RT: control of reverse transcription without RT enzyme; C2: negative control, water; C+:
positive control, HSMM; line 1: control wBM-hMSCs; line 2: laminin cells cultured in DMEM-F12 supplemented with 15% FBS; line 3: laminin cells
induced to myogenic differentiation with EGF for 7 days.
doi:10.1371/journal.pone.0045538.g004
Stem Cell Therapy for Urinary Incontinence
PLOS ONE | www.plosone.org 8 September 2012 | Volume 7 | Issue 9 | e45538
hMSC remains not well elucidated. Kawano et al. [41] reported
characteristic oscillations of membrane potential in hMSCs,
isolated by gradient density, regulated by Ca2+ channel flux. Li
et al. [42] described CACNA 1C mRNA expression in commer-
cial hMSCs and Heubach et al. [43] reported a strong expression
of the L-type calcium channel a1C subunit in all commercial hMSC
samples but low or undetectable levels for other a1D and a1S
subunits.
Since laminin cells were the only ones displaying a ‘‘myogenic
like structure’’, we evaluated the presence of L-type Ca2+ channel
a-subunits (a1C, a1D and a1S) in these differentiated cells
compared to wBM-hMSCs. All these subunits were expressed in
wBM-hMSCs up to the fourth passage of culture at consistent
levels between passages. Therefore, our data suggest their pivotal
role in some prominent biological cell function. Relative to this,
spontaneous Ca2+ oscillations created by inositol 1,4,5-triphos-
phate receptors (IP3Rs) have been recently observed in un-
differentiated hMSCs during the G1 to S transition. Thus, these
oscillations may play a role in the cell cycle progression and
proliferation, possibly due to regulation of cyclin levels [44].
Additionally, we developed a valid differentiating protocol in
vitro: in fact, under specific conditions (ITS, EGF and 5% FBS), we
Figure 5. Bisbenzimide-stained BM-hMSCs (in blue) transplanted into rat bulbocavernosus muscle. (A) 24 hours after transplantation
BM-hMSCs appear undifferentiated with a typical round shape (inset in A, scale bar = 500 mm); (B) one month after engraftment many BM-hMSCs with
elongated shape are recognizable among muscular fibers (inset in B, scale bar = 100 mm). (C) At 4 months, migration toward muscle fibers is
confirmed by elongated appearance of cells occupying peripheral position (inset b), whereas undifferentiated cells are observed in the core of graft
(inset a). Scale bar = 500 mm.
doi:10.1371/journal.pone.0045538.g005
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observed the presence of binucleated wBM-hMSCs and their
positivity to several myogenic markers (a-SMA, SA, Myosin,
Myogenin, Desmin).
Taken together, our data allow an overview of myogenic
potential of wBM-hMSCs and could clarify some controversial
basic concepts in the regenerative medicine field using BM-
hMSCs. In fact, undifferentiated wBM-hMSCs, in addition to
many early myogenic markers, express L-type calcium channel a-
subunits and could in vitro differentiate into small myogenic like
structures.
On the other hand, we show that the undifferentiated mouse
MSCs do not form myotubes efficiently, and do not fuse with
existing myotubes generated from co-cultured C2C12 cells. This is
in apparent contrast with Beier et al. (2011) [27] who showed that
MSC readily differentiate into myotubes in vitro and fuse at
relatively high efficiency when co-cultured with native myotubes.
Nevertheless, they used two kinds of differentiation media (DM):
when cultured in DM alone, MSCs resulted positive to some
myogenic markers, however ‘‘highest differentiation levels were
observed in group G8, i.e. MSCs plus myoblasts cultured under
stimulation with bFGF and dexamethasone’’. On the contrary, no
differentiation was reported when MSCs and the myogenic cell
line L6 were cultured in bFGF/dexamethasone-free DM, their
closest experimental condition to our. Our aim was to observe the
interactions between MSCs and muscle cells in ‘‘standard
conditions’’, analyzing the integration and the supporting role of
the former. Similarly, the human MSCs used for grafting were
undifferentiated in order to observe their safety, their viability
through time, and their capability of integrating into perineal
muscles.
For the in vivo studies, we transplanted human MSC into the rat
perineal muscles, as a preclinical study to establish clinical
relevance and to exclude risks for teratoma formation or undesired
cell proliferation, as already performed in transplantation studies
into the CNS [19]. On the other hand, we did not observe in the
past differences in the behavior of MSCs following mouse-to-
mouse transplantation compared to xenogenic transplants in terms
of cell proliferation or differentiation [20]. On the contrary, the in
vitro studies were performed with GFP-positive mouse MSCs i) to
exploit the interaction between MSCs and C2C12 mouse cell line
in order to understand the potential for cell fusion and induction of
MSC differentiation into muscle cells and ii) to allow the precise
identification of MSCs for their green fluorescence.
When transplanted into the pelvic muscles close to the external
urethral sphincter, BM-hMSCs survive for a long time in absence
of immunosuppression, migrate into the muscle among muscle
fibers, and towards neuromuscular endplates. Moreover, they
show low levels of cycling cells, and do not infiltrate blood vessels.
We never observed cell masses suggestive of tumorigenesis. Those
which remain close to the injection site show an immature
phenotype, whereas those in the muscle have more elongated
morphologies. When in close proximity to muscle cells, MSCs
Figure 6. Integration of BM-hMSCs in the striate muscle. (A) Bisbenzimide-labelled BM-hMSCs (in blue) appear integrated into desmin-positive
striated muscle fibers (in green). (B) At 4 months, several BM-hMSCs are located in close vicinity (arrowheads) to acetylcholine receptors (a-BTX
staining, in red) (C). Proliferative profile of transplanted BM-hMSCs at one and (D) four months after transplantation, as revealed by Ki67
immunohistochemistry (in purple). Scale bar = 50 mm.
doi:10.1371/journal.pone.0045538.g006
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display an elongated morphology aligned with muscle fiber
orientation. This is in accordance with others, who showed that
strings of peripheral MSC nuclei can be positioned along the
length of preexisting fibers [45]. Therefore, BM-hMSCs are safe
and can be easily transplanted without risk of side effects in the
pelvic muscles. Further studies are needed to support their
integration into muscle fibers, promoting their muscular transdif-
ferentiation either before or after transplantation.
The long-term survival of BM-hMSCs in the rat pelvic muscles
is not surprising. We have previously observed no immunoreaction
after long-term grafting into the mouse spinal cord in an
experimental model of amyotrophic lateral sclerosis [19]. This
property of MSCs to prevent immunoreaction [46], and that of
homing in the host bone marrow were also observed in Rhesus
monkey-to-human transplantation [47].
Our data suggest that MSCs, even though they do not fuse with
the host muscle cells, can migrate into the muscle and to the
neuromuscular junction. MSCs can deliver immunomodulatory
molecules and trophic factors [48] to support maintenance of the
endplates and muscle/motoneuron trophism as already hypothe-
sized by Canzi et al. [49] in a model of spontaneous motoneuron
degeneration, the Wobbler mouse. These factors could be also
useful in preventing age-related changes in the human urethral
rhabdosphincter [50]. Promising results were obtained with MSCs
collected from adipose tissue, recently transplanted periurethrally
in two patients with stress urinary incontinence (SUI) after radical
prostatectomy, reporting decreased incontinence [51]. On the
other hand, transplantation of adipose tissue had no significant
effects on females with SUI [52], contrarily to rats [53]. Kinebuchi
et al. report that rat BM-MSCs, transplanted into the injured
external urethral sphincter, differentiated into striated muscle cells
and peripheral nerve cells, and improved functional outcome by
reducing the abdominal leak point pressure in rats and rabbits
[54]. A tissue engineered sling with BM-MSCs and seeded
degradable silk scaffold can improve significantly SUI in female
rats. Periurethral injection of adipose stem cells with controlled
delivery of NGF improved significantly the functional outcome in
an experimental model of SUI in female rats [55]. wBM-hMSC
could be a valid alternative to the use of adipose BM-MSCs,
especially in our expansion protocol which allows to collect larger
amounts of cells to be transplanted. Since our study was limited to
investigate the feasibility, the survival and the absence of side
effects in vivo, further studies are needed to investigate the
functional outcome, and will be performed in humans.
A major problem in stem cell therapy is the large amount of
cells to be transplanted, whereas density gradient purification used
in other studies causes a huge loss of cells and requires the
collection of several mL of bone marrow under anesthesia. Our
recent data demonstrate that it is possible to isolate and obtain
a great expansion of hMSC from whole bone marrow, avoiding
initial gradient separation, and with minimal ex-vivo manipulation
[29]. Therefore, wBM hMSCs might be a very important, novel
starting point in cell therapy for SUI treatment as patients,
enrolled in a future clinical protocols, could be subjected only to
a few ml BM aspirate, performed outpatient in local anesthesia,
instead of surgical BM collection under total anesthesia.
In conclusion, some controversy still exists regarding the
possibility of MSCs to differentiate into myoblasts in situ and fuse
with the host myoblasts to form new myotubes. Our results clearly
demonstrate that they can survive long and can migrate into the
muscle, in absence of adverse side effects, i.e. they are not
tumorigenic. Also, they do not need immunosuppressive therapy
to survive. Therefore, MSCs are a promising tool for the treatment
of SUI, since they are safe and not immunogenic, can provide
a trophic and immunomodulatory support for the host. Further
studies, performed in experimental models of disease, will
elucidate the behavior and the role of MSC transplantation in
a diseased environment.
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